有症状的BA.2.86感染3周后的黏膜和血清抗体 - Suppr

Mucosal and Serum Antibodies 3 Weeks after Symptomatic BA.2.86 Infection.

作者信息

Bladh Oscar, Greilert-Norin Nina, Havervall Sebastian, Marking Ulrika, Aguilera Katherina, Alm Jessica J, Blom Kim, Åberg Mikael, Klingström Jonas, Thålin Charlotte

机构信息

Karolinska Institutet, Stockholm, Sweden.

Public Health Agency of Sweden, Solna, Sweden.

出版信息

N Engl J Med. 2023 Oct 26;389(17):1626-1628. doi: 10.1056/NEJMc2310347.

DOI:10.1056/NEJMc2310347

PMID:37888924

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10755831/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ea3/10755831/25283a6a81e9/NEJMc2310347_f1.jpg

相似文献

Mucosal and Serum Antibodies 3 Weeks after Symptomatic BA.2.86 Infection.

N Engl J Med. 2023 Oct 26;389(17):1626-1628. doi: 10.1056/NEJMc2310347.

Rapid quantitative screening assay for SARS-CoV-2 neutralizing antibodies using HiBiT-tagged virus-like particles.

J Mol Cell Biol. 2020 Nov 25;12(12):987-990. doi: 10.1093/jmcb/mjaa047.

Decline and loss of anti-SARS-CoV-2 antibodies in kidney transplant recipients in the 6 months following SARS-CoV-2 infection.

Kidney Int. 2021 Feb;99(2):486-488. doi: 10.1016/j.kint.2020.12.001.

Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351).

N Engl J Med. 2021 Jun 3;384(22):2161-2163. doi: 10.1056/NEJMc2104192. Epub 2021 Apr 7.

Persisting Neutralizing Activity to SARS-CoV-2 over Months in Sera of COVID-19 Patients.

Viruses. 2020 Nov 27;12(12):1357. doi: 10.3390/v12121357.

Compartmentalized immune responses and the local microbiota determine mucosal and systemic immunity against SARS-CoV-2.

Cell Mol Immunol. 2022 Feb;19(2):130-132. doi: 10.1038/s41423-021-00822-5. Epub 2022 Jan 7.

Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19.

J Allergy Clin Immunol. 2021 Feb;147(2):545-557.e9. doi: 10.1016/j.jaci.2020.10.040. Epub 2020 Nov 20.

Serosurvey in BNT162b2 vaccine-elicited neutralizing antibodies against authentic B.1, B.1.1.7, B.1.351, B.1.525 and P.1 SARS-CoV-2 variants.

Emerg Microbes Infect. 2021 Dec;10(1):1241-1243. doi: 10.1080/22221751.2021.1940305.

Neutralization Escape by SARS-CoV-2 Omicron Subvariant BA.4.6.

N Engl J Med. 2022 Nov 17;387(20):1904-1906. doi: 10.1056/NEJMc2212117. Epub 2022 Oct 19.

SARS-CoV-2 mucosal antibody development and persistence and their relation to viral load and COVID-19 symptoms.

Nat Commun. 2021 Sep 23;12(1):5621. doi: 10.1038/s41467-021-25949-x.

引用本文的文献

Comparison of SARS-CoV-2 spike-specific IgA and IgG in nasal secretions, saliva and serum.

Front Immunol. 2024 Mar 15;15:1346749. doi: 10.3389/fimmu.2024.1346749. eCollection 2024.

Early detection of the emerging SARS-CoV-2 BA.2.86 lineage through integrated genomic surveillance of wastewater and COVID-19 cases in Sweden, weeks 31 to 38 2023.

Euro Surveill. 2023 Nov;28(46). doi: 10.2807/1560-7917.ES.2023.28.46.2300595.

本文引用的文献

First cases of SARS-CoV-2 BA.2.86 in Denmark, 2023.

Euro Surveill. 2023 Sep;28(36). doi: 10.2807/1560-7917.ES.2023.28.36.2300460.

On the SARS-CoV-2 BA.2.86 lineage: a mutation point of view.

J Med Virol. 2023 Sep;95(9):e29079. doi: 10.1002/jmv.29079.

Mucosal immune responses following a fourth SARS-CoV-2 vaccine dose.

Lancet Microbe. 2023 Jul;4(7):e488. doi: 10.1016/S2666-5247(23)00102-7. Epub 2023 Apr 20.

Correlates of protection and viral load trajectories in omicron breakthrough infections in triple vaccinated healthcare workers.

Nat Commun. 2023 Mar 22;14(1):1577. doi: 10.1038/s41467-023-36984-1.

Anti-Spike Mucosal IgA Protection against SARS-CoV-2 Omicron Infection.

N Engl J Med. 2022 Oct 6;387(14):1333-1336. doi: 10.1056/NEJMc2209651. Epub 2022 Sep 14.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Mucosal and Serum Antibodies 3 Weeks after Symptomatic BA.2.86 Infection.

作者信息

Bladh Oscar, Greilert-Norin Nina, Havervall Sebastian, Marking Ulrika, Aguilera Katherina, Alm Jessica J, Blom Kim, Åberg Mikael, Klingström Jonas, Thålin Charlotte